{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:55:55Z","timestamp":1790207755380,"version":"4.1.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s11523-025-01132-w","type":"journal-article","created":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T06:09:24Z","timestamp":1740204564000},"page":"269-280","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["HER2 Pathway in Biliary Tract Cancer: A Snapshot of the\u00a0Current Understanding and Future Directions"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8203-1684","authenticated-orcid":false,"given":"Silvia","family":"Camera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Rossari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Foti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Vitiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Persano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica Lo","family":"Prinzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"De Cobelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Aldrighetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Cascinu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Rimini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Casadei-Gardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,22]]},"reference":[{"issue":"2","key":"1132_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J, Kelley RK, Kl\u00fcmpen HJ, Malka D, ESMO Guidelines Committee, et al. Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127\u201340. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.506.","journal-title":"Ann Oncol"},{"issue":"5","key":"1132_CR2","doi-asserted-by":"publisher","first-page":"100737","DOI":"10.1016\/j.aohep.2022.100737","volume":"27","author":"A Elvevi","year":"2022","unstructured":"Elvevi A, Laffusa A, Scaravaglio M, Rossi RE, Longarini R, Stagno AM, et al. Clinical treatment of cholangiocarcinoma: an updated comprehensive review. Ann Hepatol. 2022;27(5):100737. https:\/\/doi.org\/10.1016\/j.aohep.2022.100737.","journal-title":"Ann Hepatol"},{"issue":"18","key":"1132_CR3","doi-asserted-by":"publisher","first-page":"4446","DOI":"10.3390\/cancers15184446","volume":"15","author":"M Valery","year":"2023","unstructured":"Valery M, Vasseur D, Fachinetti F, Boil\u00e8ve A, Smolenschi C, Tarabay A, et al. Targetable molecular alterations in the treatment of biliary tract cancers: an overview of the available treatments. Cancers (Basel). 2023;15(18):4446. https:\/\/doi.org\/10.3390\/cancers15184446.","journal-title":"Cancers (Basel)."},{"issue":"9","key":"1132_CR4","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557\u201388. https:\/\/doi.org\/10.1038\/s41575-020-0310-z.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1132_CR5","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273\u201381.","journal-title":"N Engl J Med"},{"issue":"suppl_7","key":"1132_CR6","first-page":"S19","volume":"33","author":"D Oh","year":"2022","unstructured":"Oh D, He AR, Qin S, Chen LT, Okusaka T, Vogel A, et al. Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (\u00fe GC) in patients (pts) with advanced biliary tract cancer (BTC). Ann Oncol. 2022;33(suppl_7):S19\u201326.","journal-title":"Ann Oncol"},{"key":"1132_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114199","volume":"208","author":"M Rimini","year":"2024","unstructured":"Rimini M, Fornaro L, Rizzato MD, Antonuzzo L, Rossari F, Satake T, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: a large real-life worldwide population. Eur J Cancer. 2024;208: 114199. https:\/\/doi.org\/10.1016\/j.ejca.2024.114199.","journal-title":"Eur J Cancer"},{"issue":"2","key":"1132_CR8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s11523-024-01032-5","volume":"19","author":"M Rimini","year":"2024","unstructured":"Rimini M, Loi E, Rizzato MD, Pressiani T, Vivaldi C, Gusmaroli E, et al. Different genomic clusters impact on responses in advanced biliary tract cancer treated with cisplatin plus gemcitabine plus durvalumab. Target Oncol. 2024;19(2):223\u201335. https:\/\/doi.org\/10.1007\/s11523-024-01032-5.","journal-title":"Target Oncol"},{"issue":"10391","key":"1132_CR9","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, KEYNOTE-966 Investigators, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4.","journal-title":"Lancet"},{"issue":"5","key":"1132_CR10","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22(5):690\u2013701.","journal-title":"Lancet Oncol"},{"key":"1132_CR11","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:796\u2013807.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1132_CR12","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","volume":"7","author":"AX Zhu","year":"2021","unstructured":"Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol. 2021;7(11):1669\u201377. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3836.","journal-title":"JAMA Oncol"},{"key":"1132_CR13","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21:671\u201384.","journal-title":"Lancet Oncol"},{"key":"1132_CR14","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1200\/JCO.2022.40.16_suppl.4009","volume":"40","author":"L Goyal","year":"2022","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A, Morizane C, Valle JW, Karasic TB, et al. Updated results of the FOENIX-CCA2 trial: efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (ICCA) harboring FGFR2 fusions\/rearrangements. J Clin Oncol. 2022;40:4009\u20134009.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1132_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100378","volume":"7","author":"A Lamarca","year":"2022","unstructured":"Lamarca A, Edeline J, Goyal L. How I treat biliary tract cancer. ESMO Open. 2022;7(1): 100378. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100378.","journal-title":"ESMO Open."},{"key":"1132_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10555-016-9645-x","volume":"36","author":"S Galdy","year":"2017","unstructured":"Galdy S, Lamarca A, McNamara MG, Hubner RA, Cella CA, Fazio N, et al. HER2\/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? Cancer Metastasis Rev. 2017;36:141\u201357.","journal-title":"Cancer Metastasis Rev"},{"key":"1132_CR17","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","volume":"7","author":"JW Valle","year":"2017","unstructured":"Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. New horizons for precision medicine in biliary tract cancers. Cancer Discov. 2017;7:943\u201362.","journal-title":"Cancer Discov"},{"key":"1132_CR18","doi-asserted-by":"publisher","first-page":"58007","DOI":"10.18632\/oncotarget.11157","volume":"7","author":"AR Nam","year":"2016","unstructured":"Nam AR, Kim JW, Cha Y, Ha H, Park JE, Bang JH, et al. Therapeutic implication of HER2 in advanced biliary tract cancer. Oncotarget. 2016;7:58007\u201321.","journal-title":"Oncotarget"},{"issue":"1","key":"1132_CR19","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41467-023-36399-y","volume":"14","author":"JJ Harding","year":"2023","unstructured":"Harding JJ, Piha-Paul SA, Shah RH, Murphy JJ, Cleary JM, Shapiro GI, et al. Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers. Nat Commun. 2023;14(1):630. https:\/\/doi.org\/10.1038\/s41467-023-36399-y.","journal-title":"Nat Commun"},{"issue":"8","key":"1132_CR20","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1172\/JCI32278","volume":"117","author":"H Zhang","year":"2007","unstructured":"Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, et al. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Investig. 2007;117(8):2051\u20138.","journal-title":"J Clin Investig"},{"issue":"8","key":"1132_CR21","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, CLEOPATRA Study Group, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1413513.","journal-title":"N Engl J Med"},{"issue":"10371","key":"1132_CR22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","volume":"401","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401(10371):105\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(22)02420-5.","journal-title":"Lancet"},{"issue":"9742","key":"1132_CR23","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, ToGA Trial Investigators, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X.","journal-title":"Lancet"},{"key":"1132_CR24","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382:2419\u201330.","journal-title":"N Engl J Med"},{"issue":"1\u20132","key":"1132_CR25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000511919","volume":"44","author":"O Jacobi","year":"2021","unstructured":"Jacobi O, Ross JS, Goshen-Lago T, Haddad R, Moore A, Sulkes A, et al. ERBB2 pathway in biliary tract carcinoma: clinical implications of a targetable pathway. Oncol Res Treat. 2021;44(1\u20132):20\u20137. https:\/\/doi.org\/10.1159\/000511919.","journal-title":"Oncol Res Treat."},{"key":"1132_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_351354","volume":"42","author":"S Ahcene Djaballah","year":"2022","unstructured":"Ahcene Djaballah S, Daniel F, Milani A, Ricagno G, Lonardi S. HER2 in colorectal cancer: the long and winding road from negative predictive factor to positive actionable target. Am Soc Clin Oncol Educ Book. 2022;42:1\u201314. https:\/\/doi.org\/10.1200\/EDBK_351354.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1132_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102520","volume":"114","author":"Y Yu","year":"2023","unstructured":"Yu Y, Yang Y, Li H, Fan Y. Targeting HER2 alterations in non-small cell lung cancer: therapeutic breakthrough and challenges. Cancer Treat Rev. 2023;114: 102520. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102520.","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"1132_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.834104","volume":"14","author":"H Kim","year":"2022","unstructured":"Kim H, Kim R, Kim HR, Jo H, Kim H, Ha SY, et al. HER2 aberrations as a novel marker in advanced biliary tract cancer. Front Oncol. 2022;14(12): 834104. https:\/\/doi.org\/10.3389\/fonc.2022.834104.","journal-title":"Front Oncol"},{"issue":"20","key":"1132_CR29","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36(20):2105\u201322. https:\/\/doi.org\/10.1200\/JCO.2018.77.8738.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1132_CR30","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.5858\/arpa.2016-0331-CP","volume":"140","author":"AN Bartley","year":"2016","unstructured":"Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB 3rd, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med. 2016;140(12):1345\u201363. https:\/\/doi.org\/10.5858\/arpa.2016-0331-CP.","journal-title":"Arch Pathol Lab Med"},{"issue":"10","key":"1132_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206007","volume":"13","author":"A Lamarca","year":"2018","unstructured":"Lamarca A, Galdy S, Barriuso J, Moghadam S, Beckett E, Rogan J, et al. The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers. PLoS ONE. 2018;13(10):e0206007. https:\/\/doi.org\/10.1371\/journal.pone.0206007.","journal-title":"PLoS ONE"},{"key":"1132_CR32","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","volume":"22","author":"M Javle","year":"2021","unstructured":"Javle M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George B, et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021;22:1290\u2013300.","journal-title":"Lancet Oncol"},{"issue":"7","key":"1132_CR33","doi-asserted-by":"publisher","first-page":"694","DOI":"10.6004\/jnccn.2023.0035","volume":"21","author":"AB Benson","year":"2023","unstructured":"Benson AB, D\u2019Angelica MI, Abrams T, Abbott DE, Ahmed A, Anaya DA, et al. NCCN Guidelines\u00ae insights: biliary tract cancers, version 2.2023. J Natl Compr Canc Netw. 2023;21(7):694\u2013704. https:\/\/doi.org\/10.6004\/jnccn.2023.0035.","journal-title":"J Natl Compr Canc Netw"},{"key":"1132_CR34","doi-asserted-by":"publisher","first-page":"PO.18.00345","DOI":"10.1200\/PO.18.00345","volume":"3","author":"EEI Dumbrava","year":"2019","unstructured":"Dumbrava EEI, Balaji K, Raghav K, Hess K, Javle M, Blum-Murphy M, et al. Targeting ERBB2 (HER2) amplification identified by next-generation sequencing in patients with advanced or metastatic solid tumors beyond conventional indications. JCO Precis Oncol. 2019;3:PO.18.00345. https:\/\/doi.org\/10.1200\/PO.18.00345.","journal-title":"JCO Precis Oncol"},{"issue":"11","key":"1132_CR35","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.annonc.2023.08.005","volume":"34","author":"B Uzunparmak","year":"2023","unstructured":"Uzunparmak B, Haymaker C, Raso G, Masciari S, Wang L, Lin H, et al. HER2-low expression in patients with advanced or metastatic solid tumors. Ann Oncol. 2023;34(11):1035\u201346. https:\/\/doi.org\/10.1016\/j.annonc.2023.08.005.","journal-title":"Ann Oncol"},{"issue":"5","key":"1132_CR36","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/modpathol.2011.198","volume":"25","author":"J R\u00fcschoff","year":"2012","unstructured":"R\u00fcschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25(5):637\u201350. https:\/\/doi.org\/10.1038\/modpathol.2011.198.","journal-title":"Mod Pathol"},{"issue":"12","key":"1132_CR37","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1002\/ijc.30408","volume":"139","author":"F Pietrantonio","year":"2016","unstructured":"Pietrantonio F, Caporale M, Morano F, Scartozzi M, Gloghini A, De Vita F, et al. HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. Int J Cancer. 2016;139(12):2859\u201364. https:\/\/doi.org\/10.1002\/ijc.30408.","journal-title":"Int J Cancer"},{"key":"1132_CR38","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1634\/theoncologist.2019-0922","volume":"25","author":"C Vivaldi","year":"2020","unstructured":"Vivaldi C, Fornaro L, Ugolini C, Niccoli C, Musettini G, Pecora I, et al. HER2 overexpression as a poor prognostic determinant in resected biliary tract cancer. Oncologist. 2020;25:886\u201393.","journal-title":"Oncologist"},{"issue":"17","key":"1132_CR39","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","volume":"24","author":"MA Lowery","year":"2018","unstructured":"Lowery MA, Ptashkin R, Jordan E, Berger MF, Zehir A, Capanu M, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res. 2018;24(17):4154\u201361. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0078.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1132_CR40","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","volume":"24","author":"JJ Harding","year":"2023","unstructured":"Harding JJ, Fan J, Oh DY, Choi HJ, Kim JW, Chang HM, HERIZON-BTC-01 Study Group, et al. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. Lancet Oncol. 2023;24(7):772\u201382. https:\/\/doi.org\/10.1016\/S1470-2045(23)00242-5.","journal-title":"Lancet Oncol"},{"issue":"36","key":"1132_CR41","doi-asserted-by":"publisher","first-page":"5569","DOI":"10.1200\/JCO.23.00606","volume":"41","author":"Y Nakamura","year":"2023","unstructured":"Nakamura Y, Mizuno N, Sunakawa Y, Canon JL, Galsky MD, Hamilton E, et al. Tucatinib and trastuzumab for previously treated human epidermal growth factor receptor 2-positive metastatic biliary tract cancer (SGNTUC-019): a phase II basket study. J Clin Oncol. 2023;41(36):5569\u201378. https:\/\/doi.org\/10.1200\/JCO.23.00606.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1132_CR42","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S1470-2045(23)00150-X","volume":"24","author":"JH Strickler","year":"2023","unstructured":"Strickler JH, Cercek A, Siena S, Andr\u00e9 T, Ng K, Van Cutsem E, MOUNTAINEER investigators, et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 2023;24(5):496\u2013508. https:\/\/doi.org\/10.1016\/S1470-2045(23)00150-X.","journal-title":"Lancet Oncol"},{"issue":"7","key":"1132_CR43","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2020","unstructured":"Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa1914609.","journal-title":"N Engl J Med"},{"issue":"1","key":"1132_CR44","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S2468-1253(22)00335-1","volume":"8","author":"CK Lee","year":"2023","unstructured":"Lee CK, Chon HJ, Cheon J, Lee MA, Im HS, Jang JS, et al. Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14). Lancet Gastroenterol Hepatol. 2023;8(1):56\u201365. https:\/\/doi.org\/10.1016\/S2468-1253(22)00335-1.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"1132_CR45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01193","author":"V Ostwal","year":"2023","unstructured":"Ostwal V, Mandavkar S, Bhargava P, Srinivas S, Kapoor A, Shetty O, et al. Trastuzumab plus gemcitabine-cisplatin for treatment-na\u00efve human epidermal growth factor receptor 2-positive biliary tract adenocarcinoma: a multicenter, open-label, phase II study (TAB). J Clin Oncol. 2024;42(7):800\u20137.\u00a0https:\/\/doi.org\/10.1200\/JCO.23.01193.","journal-title":"J Clin Oncol"},{"issue":"19","key":"1132_CR46","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.2217\/fon-2022-0214","volume":"18","author":"A Ohba","year":"2022","unstructured":"Ohba A, Morizane C, Ueno M, Kobayashi S, Kawamoto Y, Komatsu Y, et al. Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. Future Oncol. 2022;18(19):2351\u201360. https:\/\/doi.org\/10.2217\/fon-2022-0214.","journal-title":"Future Oncol"},{"key":"1132_CR47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02010","author":"A Ohba","year":"2024","unstructured":"Ohba A, Morizane C, Kawamoto Y, Komatsu Y, Ueno M, Kobayashi S, et al. Trastuzumab deruxtecan in human epidermal growth factor receptor 2-expressing biliary tract cancer (HERB; NCCH1805): a multicenter, single-arm, phase II trial. J Clin Oncol. 2024;42(27):3207\u201317. https:\/\/doi.org\/10.1200\/JCO.23.02010.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1132_CR48","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, Gonz\u00e1lez-Mart\u00edn A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024;42(1):47\u201358. https:\/\/doi.org\/10.1200\/JCO.23.02005.","journal-title":"J Clin Oncol"},{"key":"1132_CR49","unstructured":"Clinicaltrials.gov. A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors. Retrieved from https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04450732."},{"key":"1132_CR50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.3023","author":"KN Moore","year":"2023","unstructured":"Moore KN, Sabanathan D, Du Y, Duan H, Li X, Wang F, et al. Safety and efficacy of DB-1303 in patients with advanced\/metastatic solid tumors: a multicenter, open-label, first-in-human, phase 1\/2a study. J Clin Oncol. 2023;41(suppl 16):3023.\u00a0https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.3023.","journal-title":"J Clin Oncol"},{"key":"1132_CR51","unstructured":"Clinicaltrials.gov. A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors. NCT04460456. Retrieved from https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04460456."},{"key":"1132_CR52","unstructured":"Clinicaltrials.gov. A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors. NCT04278144. Retrieved from https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04278144."},{"issue":"8","key":"1132_CR53","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38(8):947\u201353. https:\/\/doi.org\/10.1038\/s41587-020-0462-y.","journal-title":"Nat Biotechnol"},{"key":"1132_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.783305","volume":"12","author":"C Sloas","year":"2021","unstructured":"Sloas C, Gill S, Klichinsky M. Engineered CAR-macrophages as adoptive immunotherapies for solid tumors. Front Immunol. 2021;12: 783305.","journal-title":"Front Immunol"},{"issue":"suppl 16","key":"1132_CR55","doi-asserted-by":"publisher","first-page":"TPS2666","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS2666","volume":"41","author":"Y Abdou","year":"2023","unstructured":"Abdou Y, Dees EC, Mortimer JE, et al. A phase 1, first-in-human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2-overexpressing solid tumors. J Clin Oncol. 2023;41(suppl 16):TPS2666. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS2666.","journal-title":"J Clin Oncol"},{"key":"1132_CR56","unstructured":"Clinicaltrials.gov. A study to evaluate the safety and effectiveness of IAH0968 in combination with chemotherapy for the treatment of HER2-positive advanced or metastatic cancers. NCT05991518. Retrieved from https:\/\/clinicaltrials.gov\/search?intr=NCT05991518."},{"key":"1132_CR57","unstructured":"Clinicaltrials.gov. Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers. NCT04430738. Retrieved from https:\/\/clinicaltrials.gov\/search?intr=NCT04430738."},{"issue":"15_suppl","key":"1132_CR58","doi-asserted-by":"publisher","first-page":"abstr 1030","DOI":"10.1200\/JCO.2018.36.15_suppl.1030","volume":"36","author":"J Wang","year":"2018","unstructured":"Wang J, Xu B, Wang W, Fang J. An open-label, dose-escalation phase I study to evaluate RC48-ADC, a novel antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2018;36(15_suppl):abstr 1030.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"1132_CR59","doi-asserted-by":"publisher","first-page":"abstr e16059","DOI":"10.1200\/JCO.2018.36.15_suppl.e16059","volume":"36","author":"J Gong","year":"2018","unstructured":"Gong J, Shen L, Wang W, Fang J. Safety, pharmacokinetics and efficacy of RC48-ADC in a phase I study in patients with HER2-overexpression advanced solid cancer. J Clin Oncol. 2018;36(15_suppl):abstr e16059.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"1132_CR60","doi-asserted-by":"publisher","first-page":"abstr 1028","DOI":"10.1200\/JCO.2018.36.15_suppl.1028","volume":"36","author":"B Xu","year":"2018","unstructured":"Xu B, Wang J, Zhang Q, Liu Y, Feng J, Wang W, et al. An open-label, multicenter, phase Ib study to evaluate RC48-ADC in patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2018;36(15_suppl):abstr 1028.","journal-title":"J Clin Oncol"},{"key":"1132_CR61","unstructured":"Clinicaltrials.gov. A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer. NCT04329429. Retrieved from https:\/\/clinicaltrials.gov\/search?intr=NCT04329429."},{"key":"1132_CR62","unstructured":"Clinicaltrials.gov. RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2. NCT05417230. Retrieved from https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05417230."},{"key":"1132_CR63","unstructured":"Clinicaltrials.gov. RC-48 Combined With GLS-010 in HER2-overexpressed Patients With Previously Treated Unresectable Biliary Tract Cancer (RIGHT). NCT05540483. Retrieved from https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05540483."},{"key":"1132_CR64","unstructured":"Clinicaltrials.gov. Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer (TRAP-BTC). NCT06178445. Retrieved from https:\/\/clinicaltrials.gov\/study\/NCT06178445."},{"key":"1132_CR65","unstructured":"Clinicaltrials.gov. First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib\/ II Trial (HERBOT). NCT05749900. Retrieved from https:\/\/clinicaltrials.gov\/study\/NCT05749900."},{"key":"1132_CR66","unstructured":"Clinicaltrials.gov. KN026 Plus Chemotherapy \u00b1 KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma. NCT05985707. Retrieved from https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05985707."},{"issue":"7","key":"1132_CR67","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/s41591-024-02992-x","volume":"30","author":"K Shitara","year":"2024","unstructured":"Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial. Nat Med. 2024;30(7):1933\u201342. https:\/\/doi.org\/10.1038\/s41591-024-02992-x.","journal-title":"Nat Med"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01132-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01132-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01132-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T02:11:33Z","timestamp":1743041493000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01132-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,22]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1132"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01132-w","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,22]]},"assertion":[{"value":"5 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"SC, FR, SF, FV, MP, FLP, FDC, LA, SC, MR\u00a0and\u00a0ACG declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No datasets were generated or analyzed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conception and design: S. Camera, F. Rossari, M. Rimini and A. Casadei-Gardini. Writing, review, and\/or revision of the manuscript: S. Camera, F. Rossari, M. Rimini and A. Casadei-Gardini. Final approval of manuscript: All authors.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}